Paraytec develops high-performance detectors for the analytical and life sciences instrumentation market. The company has patented its innovative ActiPix™ technology for optical imaging and to measure the absorbance of fluid samples flowing in capillaries or fluid flow cuvettes. This technology allows researchers to measure the viscosity of drug formulations and the effective size of the active ingredients in these formulations.
In recent years, Paraytec has developed its CX300 instrument, which detects small numbers of fluorophore marked particles flowing in a liquid through a capillary. This technology was originally developed as a rapid detector of the Covid-19 virus in patient samples, and has now also been applied to several new applications. Braveheart owns 100% of the issued share capital in Paraytec and also provides strategic management resource to the company.
Find out more about Paraytec Limited